Cilostazol for Preventing Recurrent Stroke
This study is testing if adding cilostazol, a medication, to your current aspirin or clopidogrel treatment can help prevent future strokes and heart attacks. You may be able to join if you've had a stroke or mini-stroke (TIA) in the last 180 days and are already taking aspirin or clopidogrel. The study aims to see if this combination reduces serious heart-related events over up to four years. The current status of this study is unclear, but it plans to enroll about 2000 participants.
- Study design
- This is an interventional study comparing cilostazol to a placebo (an inactive pill) in about 2000 participants.
- What's involved
- You would take either cilostazol or a placebo pill twice daily, starting with a lower dose for the first two weeks to help with tolerability.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for up to four years after they are randomly assigned to a treatment group.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Cilostazol for Prevention of Recurrent Stroke Trial
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Maarten Lansberg, MD, PhD · PRINCIPAL_INVESTIGATOR · Stanford University
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Major adverse cardiovascular event (MACE)Up to 4 years after randomization
Time to stroke (ischemic and hemorrhagic), acute myocardial infarction, or vascular death